UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Metabolism and pharmacokinetics of oxazaphosphorines

Clinical pharmacokinetics, 2000-04, Vol.38 (4), p.291-304

2000

Volltextzugriff (PDF)

A Randomized Phase II Pharmacokinetic and Pharmacodynamic Study of Indisulam as Second-Line Therapy in Patients with Advanced Non–Small Cell Lung Cancer

Clinical cancer research, 2007-03, Vol.13 (6), p.1816-1822

2007

Volltextzugriff (PDF)

Cyclophosphamide Metabolism in Children with Non-Hodgkin’s Lymphoma

Clinical cancer research, 2004-01, Vol.10 (2), p.455-460

2004

Volltextzugriff (PDF)

Semi-physiological model describing the hematological toxicity of the anti-cancer agent indisulam

Investigational new drugs, 2005-06, Vol.23 (3), p.225-234

2005

Volltextzugriff (PDF)

Human metabolism of [(14)C]indisulam following i.v. infusion in cancer patients

Investigational new drugs, 2005-08, Vol.23 (4), p.317-330

2005

Volltextzugriff (PDF)

Quantitative determination of the novel anticancer drug E7070 (indisulam) and its metabolite (1,4-benzenedisulphonamide) in human plasma, urine and faeces by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry

Rapid communications in mass spectrometry, 2004-01, Vol.18 (23), p.2839-2848

2004

Volltextzugriff (PDF)

Cyclophosphamide metabolism in children

Cancer research (Chicago, Ill.), 1995-02, Vol.55 (4), p.803-809

1995

Volltextzugriff (PDF)

Cyclosporin neurotoxicity after chemotherapy

BMJ (Online), 1999-04, Vol.318 (7191), p.1113

1999

Volltextzugriff (PDF)

Outcome and toxicity of an ifosfamide-based soft tissue sarcoma treatment protocol in children. the importance of local therapy

Sarcoma, 1998, Vol.1998 (3-4), p.171-177

1998

Volltextzugriff (PDF)

Cyclophosphamide and ifosfamide metabolites in the cerebrospinal fluid of children

Clinical cancer research, 1997-11, Vol.3 (11), p.1985-1992

1997

Volltextzugriff (PDF)

Drug points: Cyclosporin neurotoxicity after chemotherapy

BMJ. British medical journal (International ed.), 1999-04, Vol.318 (7191), p.1113

International edition, 1999

Volltextzugriff (PDF)

Intrasubject variation in children of ifosfamide pharmacokinetics and metabolism during repeated administration

Cancer chemotherapy and pharmacology, 1996, Vol.38 (2), p.147-154

1996

Volltextzugriff (PDF)

Reproducibility of methods relating to cyclophosphamide metabolic studies--Comment\reply

JNCI : Journal of the National Cancer Institute, 1993-08, Vol.85 (15), p.1249

1993

Volltextzugriff (PDF)

Response

JNCI : Journal of the National Cancer Institute, 1993-08, Vol.85 (15), p.1250-1251

1993

Volltextzugriff (PDF)

Drug points: Cyclosporin neurotoxicity after chemotherapy

BMJ, 1999-04, Vol.318 (7191), p.1113-1113

1999

Volltextzugriff (PDF)

The Mosquito Fauna of Arizona: Species Composition and Public Health Implications

Insects (Basel, Switzerland), 2024-06, Vol.15 (6), p.432

2024

Volltextzugriff (PDF)

Nontechnical skills training in cardiothoracic surgery: A pilot study

The Journal of thoracic and cardiovascular surgery, 2022-06, Vol.163 (6), p.2155-2162.e4

2022

Volltextzugriff (PDF)

AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3β activation and RNA polymerase II inhibition

Oncogene, 2010-04, Vol.29 (16), p.2325-2336

2010

Volltextzugriff (PDF)

First-in-human phase I dose escalation study of a second-generation non-ansamycin HSP90 inhibitor, AT13387, in patients with advanced solid tumors

Clinical cancer research, 2015-01, Vol.21 (1), p.87-97

2015

Volltextzugriff (PDF)

60 Development of a gene signature to predict the anti-tumor response of the salt-inducible kinase (SIK) inhibitor OMX-0407

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A70-A70

2023

Volltextzugriff (PDF)

Identification of predictive and pharmacodynamic biomarkers associated with the first-in-class selective axl inhibitor bemcentinib across multiple phase II clinical trials

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.2559-2559

2018

Volltextzugriff (PDF)

The SPEARHEAD-1 trial of afamitresgene autoleucel (afami-cel [formerly ADP-A2M4]): Pooled analysis of cytokine release syndrome across cohorts in patients with advanced synovial sarcoma

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e14531-e14531

2023

Volltextzugriff (PDF)

Abstract 953: Development of a predictive biomarker signature for the highly potent SIK3 inhibitor OMX-0407

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (7_Supplement), p.953-953

2023

Volltextzugriff (PDF)

Abstract 514: Salt-inducible kinase inhibitor OMX-0407 drives cell-cycle arrest in vitro and in vivo: An in-depth MoA analysis by phospho-proteomics

Cancer research (Chicago, Ill.), 2024-03, Vol.84 (6_Supplement), p.514-514

2024

Volltextzugriff (PDF)

Dose-escalation study of a second-generation non-ansamycin HSP90 inhibitor, onalespib (AT13387), in combination with imatinib in patients with metastatic gastrointestinal stromal tumour

European journal of cancer (1990), 2016-07, Vol.61, p.94-101

2016

Volltextzugriff (PDF)

1 – 25 von 64

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(58)
Mit Volltextzugriff
(49)

Publikationsform

Sprache

Englisch
(64)

Erscheinungsjahr

n.n

Thema

Science & Technology
(26)
Life Sciences & Biomedicine
(25)
Humans
(18)
Oncology
(14)
Male
(13)
Female
(12)
Biological And Medical Sciences
(9)
Medical Sciences
(9)
Chemotherapy
(8)
Aged
(7)
Antineoplastic Agents
(7)
Child
(7)
Middle Aged
(7)
Pharmacology. Drug Treatments
(7)
Adult
(6)
Antineoplastic Agents - Pharmacokinetics
(6)
Adolescent
(5)
Child, Preschool
(5)
Pharmacology & Pharmacy
(5)
Animals
(4)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Metabolism and pharmacokinetics of oxazaphosphorines

A Randomized Phase II Pharmacokinetic and Pharmacodynamic Study of Indisulam as Second-Line Therapy in Patients with Advanced Non–Small Cell Lung Cancer

Cyclophosphamide Metabolism in Children with Non-Hodgkin’s Lymphoma

Semi-physiological model describing the hematological toxicity of the anti-cancer agent indisulam

Human metabolism of [(14)C]indisulam following i.v. infusion in cancer patients

Quantitative determination of the novel anticancer drug E7070 (indisulam) and its metabolite (1,4-benzenedisulphonamide) in human plasma, urine and faeces by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry

Cyclophosphamide metabolism in children

Cyclosporin neurotoxicity after chemotherapy

Outcome and toxicity of an ifosfamide-based soft tissue sarcoma treatment protocol in children. the importance of local therapy

Cyclophosphamide and ifosfamide metabolites in the cerebrospinal fluid of children

Drug points: Cyclosporin neurotoxicity after chemotherapy

Intrasubject variation in children of ifosfamide pharmacokinetics and metabolism during repeated administration

Reproducibility of methods relating to cyclophosphamide metabolic studies--Comment\reply

Response

Drug points: Cyclosporin neurotoxicity after chemotherapy

The Mosquito Fauna of Arizona: Species Composition and Public Health Implications

Nontechnical skills training in cardiothoracic surgery: A pilot study

AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3β activation and RNA polymerase II inhibition

First-in-human phase I dose escalation study of a second-generation non-ansamycin HSP90 inhibitor, AT13387, in patients with advanced solid tumors

60 Development of a gene signature to predict the anti-tumor response of the salt-inducible kinase (SIK) inhibitor OMX-0407

Identification of predictive and pharmacodynamic biomarkers associated with the first-in-class selective axl inhibitor bemcentinib across multiple phase II clinical trials

The SPEARHEAD-1 trial of afamitresgene autoleucel (afami-cel [formerly ADP-A2M4]): Pooled analysis of cytokine release syndrome across cohorts in patients with advanced synovial sarcoma

Abstract 953: Development of a predictive biomarker signature for the highly potent SIK3 inhibitor OMX-0407

Abstract 514: Salt-inducible kinase inhibitor OMX-0407 drives cell-cycle arrest in vitro and in vivo: An in-depth MoA analysis by phospho-proteomics

Dose-escalation study of a second-generation non-ansamycin HSP90 inhibitor, onalespib (AT13387), in combination with imatinib in patients with metastatic gastrointestinal stromal tumour

Suchergebnisse filtern